Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
TransEnterix, Inc. (NYSE:TRXC) resulting from allegations that
TransEnterix may have issued materially misleading business information
to the investing public.
On April 20, 2016, TransEnterix announced during aftermarket hours that
the United States Food and Drug Administration has determined that its
SurgiBot™ System does not meet the criteria for substantial equivalence
based upon the data and information TransEnterix submitted in its 510(k)
submission. On this news, shares of TransEnterix fell $2.47 per share or
over 52% to close at $2.27 per share on April 21, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by TransEnterix investors. If you purchased shares of
TransEnterix on or before April 20, 2016, please visit the firm’s
website at http://www.rosenlegal.com/cases-883.html
for more information. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com
or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160421006850/en/
Copyright Business Wire 2016